AustralieFrV1, PascalFrancis, Corpus, bibRecord, 003459

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

Identifieur interne : 003459 ( PascalFrancis/Corpus ); précédent : 003458; suivant : 003460

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

Auteurs : P. A. Vasey ; M. Gore ; R. Wilson ; G. Rustin ; H. Gabra ; J-P. Guastalla ; E. P. Lauraine ; J. Paul ; K. Carty ; S. Kaye

Source :

British journal of cancer [ 0007-0920 ] ; 2008.

RBID : Pascal:08-0315574

Descripteurs français

Pascal (Inist)
- Docétaxel, Essai clinique, Ovaire, Carboplatine, Primaire, Péritoine, Erlotinib, Récepteur facteur croissance épiderme, Cancérologie, Cancer de la trompe de Fallope, Tumeur maligne, Anticancéreux.

English descriptors

KwdEn :
- Antineoplastic agent, Cancerology, Carboplatin, Clinical trial, Docetaxel, Epidermal growth factor receptor, Erlotinib, Fallopian tube cancer, Malignant tumor, Ovary, Peritoneum, Primary.

Abstract

The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m^-2) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day^-1 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day^-1 (cohort 2b; the erlotinib dose was escalated to 100mg day^-1 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day^-1, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0007-0920`
A02	`01`			`@0 BJCAAI`
A03		`1`		`@0 Br. J. cancer`
A05				`@2 98`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers`
A11	`01`	`1`		`@1 VASEY (P. A.)`
A11	`02`	`1`		`@1 GORE (M.)`
A11	`03`	`1`		`@1 WILSON (R.)`
A11	`04`	`1`		`@1 RUSTIN (G.)`
A11	`05`	`1`		`@1 GABRA (H.)`
A11	`06`	`1`		`@1 GUASTALLA (J-P.)`
A11	`07`	`1`		`@1 LAURAINE (E. P.)`
A11	`08`	`1`		`@1 PAUL (J.)`
A11	`09`	`1`		`@1 CARTY (K.)`
A11	`10`	`1`		`@1 KAYE (S.)`
A14	`01`			`@1 CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road @2 Glasgow, Scotland GI 1 6NT @3 GBR @Z 1 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 Division of Medicine, University of Queensland @2 Brisbane Q4029 @3 AUS @Z 1 aut.`
A14	`03`			`@1 Royal Marsden Hospital, Fulham Road @2 London SW15 3SW @3 GBR @Z 2 aut.`
A14	`04`			`@1 Belfast City Hospital, Lisbum Road @2 Belfast, Ireland BT9 7AB @3 GBR @Z 3 aut.`
A14	`05`			`@1 Mount Vernon Hospital, Rickmansworth Road @2 Northwood, Hertfordshire HA6 2RN @3 GBR @Z 4 aut.`
A14	`06`			`@1 Western General Hospital, Crewe Road South @2 Edinburgh, Scotland EH4 2XU @3 GBR @Z 5 aut.`
A14	`07`			`@1 Centre Léon-Bérard, rue Laennec @2 69373, Lyon @3 FRA @Z 6 aut.`
A14	`08`			`@1 Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame @2 75181 Paris @3 FRA @Z 7 aut.`
A14	`09`			`@1 Royal Marsden Hospital, Downs Road @2 Sutton, Surrey SM2 5PT @3 GBR @Z 10 aut.`
A17	`01`	`1`		`@1 Scottish Gynaecological Cancer Trials Group @3 INC`
A20				`@1 1774-1780`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6925 @5 354000198007140100`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.`
A47	`01`	`1`		`@0 08-0315574`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 British journal of cancer`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m^-2) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day^-1 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day^-1 (cohort 2b; the erlotinib dose was escalated to 100mg day^-1 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day^-1, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.
C02	`01`	`X`		`@0 002B04`
C02	`02`	`X`		`@0 002B20C02`
C03	`01`	`X`	`FRE`	`@0 Docétaxel @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Docetaxel @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Docetaxel @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Essai clinique @5 02`
C03	`02`	`X`	`ENG`	`@0 Clinical trial @5 02`
C03	`02`	`X`	`SPA`	`@0 Ensayo clínico @5 02`
C03	`03`	`X`	`FRE`	`@0 Ovaire @5 03`
C03	`03`	`X`	`ENG`	`@0 Ovary @5 03`
C03	`03`	`X`	`SPA`	`@0 Ovario @5 03`
C03	`04`	`X`	`FRE`	`@0 Carboplatine @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Carboplatin @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Carboplatino @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Primaire @5 05`
C03	`05`	`X`	`ENG`	`@0 Primary @5 05`
C03	`05`	`X`	`SPA`	`@0 Primario @5 05`
C03	`06`	`X`	`FRE`	`@0 Péritoine @5 06`
C03	`06`	`X`	`ENG`	`@0 Peritoneum @5 06`
C03	`06`	`X`	`SPA`	`@0 Peritoneo @5 06`
C03	`07`	`X`	`FRE`	`@0 Erlotinib @2 FR @5 07`
C03	`07`	`X`	`ENG`	`@0 Erlotinib @2 FR @5 07`
C03	`07`	`X`	`SPA`	`@0 Erlotinib @2 FR @5 07`
C03	`08`	`X`	`FRE`	`@0 Récepteur facteur croissance épiderme @5 08`
C03	`08`	`X`	`ENG`	`@0 Epidermal growth factor receptor @5 08`
C03	`08`	`X`	`SPA`	`@0 Receptor del factor de crecimiento epidérmico @5 08`
C03	`09`	`X`	`FRE`	`@0 Cancérologie @5 09`
C03	`09`	`X`	`ENG`	`@0 Cancerology @5 09`
C03	`09`	`X`	`SPA`	`@0 Cancerología @5 09`
C03	`10`	`X`	`FRE`	`@0 Cancer de la trompe de Fallope @2 NM @5 10`
C03	`10`	`X`	`ENG`	`@0 Fallopian tube cancer @2 NM @5 10`
C03	`10`	`X`	`SPA`	`@0 Cáncer de falopio del tubo @2 NM @5 10`
C03	`11`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 13`
C03	`11`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 13`
C03	`11`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 13`
C03	`12`	`X`	`FRE`	`@0 Anticancéreux @5 25`
C03	`12`	`X`	`ENG`	`@0 Antineoplastic agent @5 25`
C03	`12`	`X`	`SPA`	`@0 Anticanceroso @5 25`
C07	`01`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`01`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`01`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`02`	`X`	`FRE`	`@0 Antimitotique @5 37`
C07	`02`	`X`	`ENG`	`@0 Antimitotic @5 37`
C07	`02`	`X`	`SPA`	`@0 Antimitótico @5 37`
C07	`03`	`X`	`FRE`	`@0 Dérivé du taxane @5 38`
C07	`03`	`X`	`ENG`	`@0 Taxane derivatives @5 38`
C07	`03`	`X`	`SPA`	`@0 Taxane derivado @5 38`
C07	`04`	`X`	`FRE`	`@0 Platine II Complexe @2 NC @2 NA @5 39`
C07	`04`	`X`	`ENG`	`@0 Platinum II Complexes @2 NC @2 NA @5 39`
C07	`04`	`X`	`SPA`	`@0 Platino II Complejo @2 NC @2 NA @5 39`
C07	`05`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 40`
C07	`05`	`X`	`ENG`	`@0 Enzyme inhibitor @5 40`
C07	`05`	`X`	`SPA`	`@0 Inhibidor enzima @5 40`
C07	`06`	`X`	`FRE`	`@0 Dérivé de la quinazoline @2 FR @5 41`
C07	`06`	`X`	`ENG`	`@0 Quinazoline derivatives @2 FR @5 41`
C07	`07`	`X`	`FRE`	`@0 Protein-tyrosine kinase @2 FE @5 42`
C07	`07`	`X`	`ENG`	`@0 Protein-tyrosine kinase @2 FE @5 42`
C07	`07`	`X`	`SPA`	`@0 Protein-tyrosine kinase @2 FE @5 42`
C07	`08`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`08`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`08`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`09`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`09`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`09`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`10`	`X`	`FRE`	`@0 Inhibiteur de la tyrosine kinase @5 43`
C07	`10`	`X`	`ENG`	`@0 Tyrosine kinase inhibitor @5 43`
C07	`10`	`X`	`SPA`	`@0 Inhibidor tyrosine kinase @5 43`
C07	`11`	`X`	`FRE`	`@0 Appareil génital femelle @5 45`
C07	`11`	`X`	`ENG`	`@0 Female genital system @5 45`
C07	`11`	`X`	`SPA`	`@0 Aparato genital hembra @5 45`
C07	`12`	`X`	`FRE`	`@0 Pathologie de l'appareil génital femelle @5 46`
C07	`12`	`X`	`ENG`	`@0 Female genital diseases @5 46`
C07	`12`	`X`	`SPA`	`@0 Aparato genital hembra patología @5 46`
C07	`13`	`X`	`FRE`	`@0 Pathologie de la trompe de Fallope @5 47`
C07	`13`	`X`	`ENG`	`@0 Fallopian tube pathology @5 47`
C07	`13`	`X`	`SPA`	`@0 Trompa Falopio patología @5 47`
N21				`@1 196`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0315574 INIST
ET :	A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
AU :	VASEY (P. A.); GORE (M.); WILSON (R.); RUSTIN (G.); GABRA (H.); GUASTALLA (J-P.); LAURAINE (E. P.); PAUL (J.); CARTY (K.); KAYE (S.)
AF :	CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road/Glasgow, Scotland GI 1 6NT/Royaume-Uni (1 aut., 8 aut., 9 aut.); Division of Medicine, University of Queensland/Brisbane Q4029/Australie (1 aut.); Royal Marsden Hospital, Fulham Road/London SW15 3SW/Royaume-Uni (2 aut.); Belfast City Hospital, Lisbum Road/Belfast, Ireland BT9 7AB/Royaume-Uni (3 aut.); Mount Vernon Hospital, Rickmansworth Road/Northwood, Hertfordshire HA6 2RN/Royaume-Uni (4 aut.); Western General Hospital, Crewe Road South/Edinburgh, Scotland EH4 2XU/Royaume-Uni (5 aut.); Centre Léon-Bérard, rue Laennec/69373, Lyon/France (6 aut.); Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame/75181 Paris/France (7 aut.); Royal Marsden Hospital, Downs Road/Sutton, Surrey SM2 5PT/Royaume-Uni (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	British journal of cancer; ISSN 0007-0920; Coden BJCAAI; Royaume-Uni; Da. 2008; Vol. 98; No. 11; Pp. 1774-1780; Bibl. 1 p.
LA :	Anglais
EA :	The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m^-2) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day^-1 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day^-1 (cohort 2b; the erlotinib dose was escalated to 100mg day^-1 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day^-1, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.
CC :	002B04; 002B20C02
FD :	Docétaxel; Essai clinique; Ovaire; Carboplatine; Primaire; Péritoine; Erlotinib; Récepteur facteur croissance épiderme; Cancérologie; Cancer de la trompe de Fallope; Tumeur maligne; Anticancéreux
FG :	Cancer; Antimitotique; Dérivé du taxane; Platine II Complexe; Inhibiteur enzyme; Dérivé de la quinazoline; Protein-tyrosine kinase; Transferases; Enzyme; Inhibiteur de la tyrosine kinase; Appareil génital femelle; Pathologie de l'appareil génital femelle; Pathologie de la trompe de Fallope
ED :	Docetaxel; Clinical trial; Ovary; Carboplatin; Primary; Peritoneum; Erlotinib; Epidermal growth factor receptor; Cancerology; Fallopian tube cancer; Malignant tumor; Antineoplastic agent
EG :	Cancer; Antimitotic; Taxane derivatives; Platinum II Complexes; Enzyme inhibitor; Quinazoline derivatives; Protein-tyrosine kinase; Transferases; Enzyme; Tyrosine kinase inhibitor; Female genital system; Female genital diseases; Fallopian tube pathology
SD :	Docetaxel; Ensayo clínico; Ovario; Carboplatino; Primario; Peritoneo; Erlotinib; Receptor del factor de crecimiento epidérmico; Cancerología; Cáncer de falopio del tubo; Tumor maligno; Anticanceroso
LO :	INIST-6925.354000198007140100
ID :	08-0315574

Links to Exploration step

Pascal:08-0315574

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</title>
<author><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name>
<affiliation><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1>
<s2>Brisbane Q4029</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name>
<affiliation><inist:fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1>
<s2>London SW15 3SW</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name>
<affiliation><inist:fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1>
<s2>Belfast, Ireland BT9 7AB</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name>
<affiliation><inist:fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1>
<s2>Northwood, Hertfordshire HA6 2RN</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name>
<affiliation><inist:fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1>
<s2>Edinburgh, Scotland EH4 2XU</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name>
<affiliation><inist:fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1>
<s2>69373, Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name>
<affiliation><inist:fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1>
<s2>75181 Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name>
<affiliation><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name>
<affiliation><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name>
<affiliation><inist:fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1>
<s2>Sutton, Surrey SM2 5PT</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0315574</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0315574 INIST</idno>
<idno type="RBID">Pascal:08-0315574</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003459</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</title>
<author><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name>
<affiliation><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1>
<s2>Brisbane Q4029</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name>
<affiliation><inist:fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1>
<s2>London SW15 3SW</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name>
<affiliation><inist:fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1>
<s2>Belfast, Ireland BT9 7AB</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name>
<affiliation><inist:fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1>
<s2>Northwood, Hertfordshire HA6 2RN</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name>
<affiliation><inist:fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1>
<s2>Edinburgh, Scotland EH4 2XU</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name>
<affiliation><inist:fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1>
<s2>69373, Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name>
<affiliation><inist:fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1>
<s2>75181 Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name>
<affiliation><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name>
<affiliation><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name>
<affiliation><inist:fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1>
<s2>Sutton, Surrey SM2 5PT</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Carboplatin</term>
<term>Clinical trial</term>
<term>Docetaxel</term>
<term>Epidermal growth factor receptor</term>
<term>Erlotinib</term>
<term>Fallopian tube cancer</term>
<term>Malignant tumor</term>
<term>Ovary</term>
<term>Peritoneum</term>
<term>Primary</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Docétaxel</term>
<term>Essai clinique</term>
<term>Ovaire</term>
<term>Carboplatine</term>
<term>Primaire</term>
<term>Péritoine</term>
<term>Erlotinib</term>
<term>Récepteur facteur croissance épiderme</term>
<term>Cancérologie</term>
<term>Cancer de la trompe de Fallope</term>
<term>Tumeur maligne</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m<sup>-2</sup>
) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day<sup>-1</sup>
 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day<sup>-1</sup>
 (cohort 2b; the erlotinib dose was escalated to 100mg day<sup>-1</sup>
 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day<sup>-1</sup>
, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0007-0920</s0>
</fA01>
<fA02 i1="01"><s0>BJCAAI</s0>
</fA02>
<fA03 i2="1"><s0>Br. J. cancer</s0>
</fA03>
<fA05><s2>98</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VASEY (P. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GORE (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>WILSON (R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RUSTIN (G.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GABRA (H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GUASTALLA (J-P.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LAURAINE (E. P.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PAUL (J.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CARTY (K.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>KAYE (S.)</s1>
</fA11>
<fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1>
<s2>Brisbane Q4029</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1>
<s2>London SW15 3SW</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1>
<s2>Belfast, Ireland BT9 7AB</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1>
<s2>Northwood, Hertfordshire HA6 2RN</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1>
<s2>Edinburgh, Scotland EH4 2XU</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1>
<s2>69373, Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1>
<s2>75181 Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1>
<s2>Sutton, Surrey SM2 5PT</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Scottish Gynaecological Cancer Trials Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>1774-1780</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6925</s2>
<s5>354000198007140100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0315574</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>British journal of cancer</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m<sup>-2</sup>
) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day<sup>-1</sup>
 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day<sup>-1</sup>
 (cohort 2b; the erlotinib dose was escalated to 100mg day<sup>-1</sup>
 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day<sup>-1</sup>
, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20C02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Docétaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Ovaire</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Ovary</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ovario</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Carboplatine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Carboplatin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Carboplatino</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Primaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Primary</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Primario</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Péritoine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Peritoneum</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Peritoneo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Erlotinib</s0>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Erlotinib</s0>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Erlotinib</s0>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Récepteur facteur croissance épiderme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Epidermal growth factor receptor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Receptor del factor de crecimiento epidérmico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Cancer de la trompe de Fallope</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Fallopian tube cancer</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Cáncer de falopio del tubo</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Antimitotique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Antimitotic</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Antimitótico</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Dérivé du taxane</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Taxane derivatives</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Taxane derivado</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Platine II Complexe</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Platinum II Complexes</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Platino II Complejo</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Dérivé de la quinazoline</s0>
<s2>FR</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Quinazoline derivatives</s0>
<s2>FR</s2>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Protein-tyrosine kinase</s0>
<s2>FE</s2>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Protein-tyrosine kinase</s0>
<s2>FE</s2>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Protein-tyrosine kinase</s0>
<s2>FE</s2>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Inhibiteur de la tyrosine kinase</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Tyrosine kinase inhibitor</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Inhibidor tyrosine kinase</s0>
<s5>43</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Appareil génital femelle</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Female genital system</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Aparato genital hembra</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Pathologie de l'appareil génital femelle</s0>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Female genital diseases</s0>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Aparato genital hembra patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Pathologie de la trompe de Fallope</s0>
<s5>47</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Fallopian tube pathology</s0>
<s5>47</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Trompa Falopio patología</s0>
<s5>47</s5>
</fC07>
<fN21><s1>196</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0315574 INIST</NO>
<ET>A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</ET>
<AU>VASEY (P. A.); GORE (M.); WILSON (R.); RUSTIN (G.); GABRA (H.); GUASTALLA (J-P.); LAURAINE (E. P.); PAUL (J.); CARTY (K.); KAYE (S.)</AU>
<AF>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road/Glasgow, Scotland GI 1 6NT/Royaume-Uni (1 aut., 8 aut., 9 aut.); Division of Medicine, University of Queensland/Brisbane Q4029/Australie (1 aut.); Royal Marsden Hospital, Fulham Road/London SW15 3SW/Royaume-Uni (2 aut.); Belfast City Hospital, Lisbum Road/Belfast, Ireland BT9 7AB/Royaume-Uni (3 aut.); Mount Vernon Hospital, Rickmansworth Road/Northwood, Hertfordshire HA6 2RN/Royaume-Uni (4 aut.); Western General Hospital, Crewe Road South/Edinburgh, Scotland EH4 2XU/Royaume-Uni (5 aut.); Centre Léon-Bérard, rue Laennec/69373, Lyon/France (6 aut.); Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame/75181 Paris/France (7 aut.); Royal Marsden Hospital, Downs Road/Sutton, Surrey SM2 5PT/Royaume-Uni (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>British journal of cancer; ISSN 0007-0920; Coden BJCAAI; Royaume-Uni; Da. 2008; Vol. 98; No. 11; Pp. 1774-1780; Bibl. 1 p.</SO>
<LA>Anglais</LA>
<EA>The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m<sup>-2</sup>
) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day<sup>-1</sup>
 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day<sup>-1</sup>
 (cohort 2b; the erlotinib dose was escalated to 100mg day<sup>-1</sup>
 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day<sup>-1</sup>
, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.</EA>
<CC>002B04; 002B20C02</CC>
<FD>Docétaxel; Essai clinique; Ovaire; Carboplatine; Primaire; Péritoine; Erlotinib; Récepteur facteur croissance épiderme; Cancérologie; Cancer de la trompe de Fallope; Tumeur maligne; Anticancéreux</FD>
<FG>Cancer; Antimitotique; Dérivé du taxane; Platine II Complexe; Inhibiteur enzyme; Dérivé de la quinazoline; Protein-tyrosine kinase; Transferases; Enzyme; Inhibiteur de la tyrosine kinase; Appareil génital femelle; Pathologie de l'appareil génital femelle; Pathologie de la trompe de Fallope</FG>
<ED>Docetaxel; Clinical trial; Ovary; Carboplatin; Primary; Peritoneum; Erlotinib; Epidermal growth factor receptor; Cancerology; Fallopian tube cancer; Malignant tumor; Antineoplastic agent</ED>
<EG>Cancer; Antimitotic; Taxane derivatives; Platinum II Complexes; Enzyme inhibitor; Quinazoline derivatives; Protein-tyrosine kinase; Transferases; Enzyme; Tyrosine kinase inhibitor; Female genital system; Female genital diseases; Fallopian tube pathology</EG>
<SD>Docetaxel; Ensayo clínico; Ovario; Carboplatino; Primario; Peritoneo; Erlotinib; Receptor del factor de crecimiento epidérmico; Cancerología; Cáncer de falopio del tubo; Tumor maligno; Anticanceroso</SD>
<LO>INIST-6925.354000198007140100</LO>
<ID>08-0315574</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003459 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003459 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0315574
   |texte=   A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri